NASDAQ:BSTC - Nasdaq -
Mentions: ENDP
NEW YORK, NY / ACCESSWIRE / November 18, 2020 / Halper Sadeh LLP, a global investor rights law firm, announces it is investigating: BioSpecifics Technologies Corp. (NASDAQ:BSTC) concerning potential violations of the federal securities laws and/or breaches of fiduciary duties relating to its sale to Endo International plc for $88.50 per share. If you are a BioSpecifics shareholder, click on this link to learn more about your rights and
Mentions: ENDP
BioSpecifics (BSTC) delivered earnings and revenue surprises of 315.79% and 106.15%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
- Endo acquisition of BioSpecifics expected to close in 4Q20
NEW YORK, NY / ACCESSWIRE / November 7, 2020 /Halper Sadeh LLP, a global investor rights law firm, announces it is investigating: BioSpecifics Technologies Corp. (NASDAQ:BSTC) concerning potential violations of the federal securities laws and/or breaches of fiduciary duties relating to its sale to Endo International plc for $88.50 per share. If you are a BioSpecifics shareholder, click on this link to learn more about your rights and
Mentions: ENDP
BioSpecifics (BSTC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Endo's (ENDP) earnings and sales beat estimates in the third quarter. The company raises its annual outlook.
URGENT - TENDER OFFER EXPIRES DECEMBER 1, 2020
Mentions: ENDP
NEW YORK, NY / ACCESSWIRE / October 27, 2020 / Halper Sadeh LLP, a global investor rights law firm, announces it is investigating: GCI Liberty, Inc. (NASDAQ:GLIBA) concerning potential violations of the federal securities laws and/or breaches of fiduciary duties relating to its sale to Liberty Broadband Corporation. Visit our website to learn more about your legal rights and options:
The biotech sector was in focus as Biogen's (BIIB) Q3 results disappoint, Vertex (VRTX) stops study and Regeneron's (REGN) Ebola drug gets FDA approval.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 20) Aileron Therapeutics Inc (...
Endo (ENDP) gains from the acquisition of commercial-stage biopharmaceutical company, BioSpecifics Technologies Corp.